8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

October 22, 2026 updated by: Mark Frye, Mayo Clinic

An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression

This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS ® for this indication.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

77

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic in Rochester
    • Ohio
      • Mason, Ohio, United States, 45040
        • Lindner Center of Hope

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  1. Male or female between 18 and 65 years of age
  2. Bipolar I or II disorder as confirmed by structured diagnostic clinical interview for DSM-IV-TR.
  3. Subsyndromal depressive symptoms or major depressive episode unresponsive to steady and stable (ie, at least 2 weeks) mood stabilization (eg, lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
  4. Antidepressant therapy is allowed in the study as long as patients are also on a mood stabilizer. Patients will be enrolled provided that any needed modifications to the antidepressant would be made at least two weeks prior to randomization.
  5. Patients receiving psychotherapy will be allowed to be randomized provided therapy frequency does not change during the 8-week blinded phase.
  6. Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) ≥9, and the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale ≥ 3.
  7. Patients on stimulants for comorbid attention deficit disorder (ADHD) and/or binge eating disorder (BED) will be enrolled provided that the stimulant can be tapered and discontinued at least one week prior to randomization; symptom severity inclusion criteria 4.1.3 or presence of subsyndromal symptoms must be met again prior to randomization.
  8. Patients with a prescribed opiate (eg. hydroxicodone) or other pain intervention for acute or chronic pain management will be allowed provided they: 1) use of a prescribed opiate or other pain intervention at a recommendation dose and established duration; 2) show no evidence of prescription misuse; 3) do not meet abuse or dependence criteria by SCID; 4) no known significant pharmacological interactions.
  9. Ability to travel for the assessment visits.

Exclusion Criteria

  1. Inability to provide written informed consent.

  2. Inability to understand English.

  3. Score less than 86% correct (ie, one wrong) on comprehension assessment that reviews study goals.

  4. Clinically significant signs of acute suicidality from any of the following assessments:

    1. Response of > 2 on question #12 of QIDS-C or
    2. Response = 3 on the SCID Module A- #A19
  5. Medically serious suicide attempt within the past 6 months (medically serious defined as an ED evaluation and procedure and/or admit to inpatient unit such as internal medicine, cardiac, or ICU).

  6. Concomitant treatment with monoamine oxidase inhibitors (MAOIs); also, within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.

  7. Baseline Young Mania Rating Scale (YMRS) score ≥ 12.

  8. Patients with active psychosis (measured by a score >4 on YMRS question #8) or a diagnosis of schizophrenia, schizoaffective disorder, delusional, or schizophreniform disorder identified by structured clinical interview for DSM-IV-TR.

  9. Active abuse or dependence of alcohol, opiates, or cannabis (nicotine dependence will be an exception) by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 3 months can be randomized.

  10. Positive toxicology screen for drugs of abuse (ie, cocaine, methamphetamine, illegal opiates).

  11. Positive toxicology screen for cannabis and a cannabis use disorder by structured clinical interview for DSM-IV-TR. Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less

  12. Known lifetime history of cocaine or methamphetamine abuse or dependence identified by structured clinical interview for DSM-IV-TR.

  13. Active stimulant prescription abuse or dependence by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 6 months can be randomized.

  14. Known lifetime history of stimulant-induced mania.

  15. Known hypersensitivity, such as angioedema or anaphylaxis, to amphetamines or other ingredients of MYDAYIS.

  16. Clinically unstable medical disease.

  17. Known history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problems.

  18. ECG with clinically significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).

  19. Uncontrolled hypertension (>160/100) or tachycardia (heart rate >110).

  20. History of grand mal seizure; history of febrile seizure as infant permitted.

  21. Established vasculopathy or history of Raynaud's phenomena.

  22. Narrow angle glaucoma.

  23. Chronic kidney disease (CKD) > stage IIIa (GFR 40-59).

  24. Tourette syndrome.

  25. Women who are pregnant, lactating or of child-bearing potential not using at least one adequate contraceptive measure (ie, hormonal contraception-birth control pills, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse).

  26. Current positive test for SARS-CoV-2; those with previous COVID-19 illness and those who test positive for SARS-CoV-2 any time after starting study drug or placebo will be included.

  27. Otherwise excluded for administrative reasons and/or clinician judgment.

  28. Daily use of lorazepam (Ativan) at doses > 2 mg per day (or dose equivalent: clonazepam (Klonopin) > 1 mg, alprazolam (Xanax) > 1-2 mg, or diazepam (Valium) >20 mg) [58].

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Mydayis - Active

MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®

Other Names:
  • d-amphetamine / l-amphetamine
Placebo Comparator: Placebo

Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Matching placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
Time Frame: Baseline to week 8

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean percent reduction from baseline in participants' total MADRS score, with greater percent reductions indicating greater improvement in depressive symptoms.

Baseline to week 8
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension
Time Frame: Week 8 to Week 16

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean absolute change from week 8 to week 16 in participants' total MADRS score. Negative values indicate a reduction in depressive symptom severity.

Week 8 to Week 16

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) Score
Time Frame: Baseline to Week 8

The QIDS-C-16 (Quick Inventory of Depressive Symptomatology - Clinician) and QIDS-SR-16 (Quick Inventory of Depressive Symptomatology - Self Report) are 16-item questionnaires designed to assess the severity of depressive symptoms. They are widely used by healthcare providers to monitor treatment progress and symptom changes over time. They are scored the same. Scores are calculated by summing the responses to nine core symptom domains. The total score ranges from 0 to 27, with higher scores indicating greater depression severity. The outcome measure was mean percent reduction from baseline in total QIDS-C-16 and QIDS-SR-16 scores, with greater reductions indicating greater improvement in depressive symptoms.

Baseline to Week 8
Remission
Time Frame: Baseline to Week 8

The number of subjects who had treatment remission defined as having a Montgomery-Asberg Depression Rating Scale (MADRS) score < 10. (Score Range 0-60)

Baseline to Week 8
Change in General Anxiety Disorder 7-item (GAD-7) Scale Score
Time Frame: Baseline to Week 8 visit 10

The GAD-7 scale is used to assess anxiety symptoms in individuals. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

Baseline to Week 8 visit 10
Response
Time Frame: Baseline to Week 8 visit 10

The number of subjects who had a treatment response defined as a 50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score (Range: 0-60).

Baseline to Week 8 visit 10
Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score
Time Frame: Baseline to Week 8 visit 10

The number of subjects who had improvement in their CGI-I score. This scale evaluates how much the patient's illness has improved or worsened relative to their baseline state (prior to starting treatment). Scores range from 1-7 with lower scores indicating higher improvement.

Baseline to Week 8 visit 10
Change in Young Mania Rating Scale (YMRS) Score
Time Frame: Baseline to Week 8

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean percent change from baseline in the total YMRS score. A greater decrease from baseline (more negative percent change) indicates improvement in manic symptoms.

Baseline to Week 8
Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension
Time Frame: Week 8 to Week 16

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean change from week 8 to week 16 in the total YMRS score.

Week 8 to Week 16
Change in Epworth Sleepiness Scale (ESS) Score
Time Frame: Baseline to Week 8

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that measures the average level of daytime sleepiness. By rating the likelihood of dozing off in 8 daily scenarios, a total score ranging from 0 to 24 is calculated. A higher score indicates greater daytime sleepiness and increased severity of sleepiness symptoms. The outcome measure was the mean percent change from baseline in the total ESS score. A greater decrease from baseline (more negative percent change) indicates improvement in daytime sleepiness.

Baseline to Week 8
Change in Fatigue Severity Scale (FSS) Score
Time Frame: Baseline to Week 8

The Fatigue Severity Scale (FSS) evaluates how fatigue impacts daily life. It contains 9 statements, each rated on a 1-to-7 scale (1 = strongly disagree, 7 = strongly agree). Total scores range from 9 to 63 with higher scores indicating worse fatigue. The outcome measure was the mean percent change from baseline in the total FSS score. A greater decrease from baseline (more negative percent change) indicates improvement in fatigue severity.

Baseline to Week 8
Change in Binge Eating Scale (BES) Score
Time Frame: Baseline to Week 8

The Binge Eating Scale (BES) is a self-reported questionnaire designed to assess the presence and severity of binge eating behaviors and characteristics associated with binge eating. Total scores range from 0 to 48 with higher scores indicating greater severity of binge eating symptoms.

Baseline to Week 8
Change in Rapid Eating and Activity Assessment for Patients (REAP) Score
Time Frame: Baseline to Week 8

The Rapid Eating and Activity Assessment for Patients (REAP) is a self-reported questionnaire used to assess dietary habits and physical activity behaviors. Total REAP scores range from 0 to 27 with higher scores indicating healthier nutrition and physical activity behaviors. The outcome measure was the mean percent change from baseline in the total REAP score. A greater increase from baseline indicates improvement in dietary and physical activity behaviors.

Baseline to Week 8
Change in Digit Symbol Substitution Test (DSST) Score
Time Frame: Baseline to Week 8

The Digit Symbol Substitution Test (DSST) is a neuropsychological assessment of cognitive performance that measures processing speed, working memory, and visuomotor coordination. Participants are required to match symbols to corresponding number according to a provided key within a fixed time period of 90 seconds. The raw score is simply the total number of correctly matched symbols completed within the time limit (90 seconds). Scores range from 0 to the total number of correct responses achieved, with higher scores indicating better cognitive performance. The outcome measure was the mean percent change from baseline in DSST score. A greater increase from baseline indicates improvement in cognitive performance.

Baseline to Week 8
Morningness-Eveningness Questionnaire (MEQ) Score
Time Frame: Baseline

The Morningness-Eveningness Questionnaire (MEQ) is a self-assessment tool used to determine a person's preferred timing for sleep and peak alertness during the day. Total scores range from 16 to 86 with higher scores indicating a stronger morning preference, whereas lower scores indicate a stronger evening preference.

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Mark A Frye, Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 17, 2020

Primary Completion (Actual)

July 25, 2025

Study Completion (Actual)

July 25, 2025

Study Registration Dates

First Submitted

December 4, 2019

First Submitted That Met QC Criteria

January 16, 2020

First Posted (Actual)

January 22, 2020

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

October 22, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 19-001722

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.